DiaMedica Therapeutics (DMAC) Competitors

Stoke Therapeutics (NASDAQ:STOK) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Is STOK or DMAC more profitable?

Stoke Therapeutics has a net margin of 26.25% compared to DiaMedica Therapeutics' net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	26.25%	18.32%	15.48%
DiaMedica Therapeutics	N/A	-78.99%	-69.94%

Which has more risk and volatility, STOK or DMAC?

Stoke Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in STOK or DMAC?

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend STOK or DMAC?

Stoke Therapeutics currently has a consensus target price of $25.17, indicating a potential upside of 38.20%. DiaMedica Therapeutics has a consensus target price of $12.33, indicating a potential upside of 104.53%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
DiaMedica Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation & earnings, STOK or DMAC?

DiaMedica Therapeutics has lower revenue, but higher earnings than Stoke Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$36.56M	27.30	-$88.98M	$0.79	23.05
DiaMedica Therapeutics	N/A	N/A	-$24.44M	-$0.64	-9.42

Does the media favor STOK or DMAC?

In the previous week, Stoke Therapeutics had 22 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 35 mentions for Stoke Therapeutics and 13 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.77 beat Stoke Therapeutics' score of 0.63 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DiaMedica Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Stoke Therapeutics beats DiaMedica Therapeutics on 11 of the 16 factors compared between the two stocks.